一种新型蛋白质-配体捕获系统,用于从天然产物中快速筛选和发现PD-L1的小分子抑制剂。
A New Protein-Ligand Trapping System to Rapidly Screen and Discover Small-Molecule Inhibitors of PD-L1 from Natural Products.
作者信息
Huang Yazhuo, Sun Senfeng, Yin Runxin, Lin Zongtao, Wang Daidong, Wang Wanwan, Fu Xiangyu, Wang Jing, Lei Xinyu, Sun Mimi, Chen Shizhong, Wang Hong
机构信息
School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104, USA.
出版信息
Molecules. 2025 Apr 14;30(8):1754. doi: 10.3390/molecules30081754.
Chinese herbal medicines have played a significant role in the development of new and effective drugs, but how to identify the active ingredients from complex extracts of traditional Chinese herbal medicines was a research difficulty. In recent years, few studies have focused on high-efficiency identification of small-molecule inhibitors of Programmed Death Ligand 1 with lower antigenicity and flexible structure tunability. In order to identify small molecule inhibitors of PD-L1 from complex Chinese herbal extracts, this study established a protein-ligand trapping system based on high-performance liquid chromatography coupled with a photo-diode array detector, ion trap/quadrupole time-of-flight tandem mass spectrometry, and a Programmed Death Ligand 1 affinity chromatography unit (ACPD-L1-HPLC-PDA-IT-TOF (Q-TOF)-MS) to rapidly screen and identify small-molecule inhibitors of Programmed Death Ligand 1 from (L.) Lam. Fourteen components were then identified as PD-L1 binders, and surface plasmon resonance (SPR) validation results showed that six of them-magnoflorine (), nitidine (), chelerythrine (), jatrorrhizine (), toddaculin (), and toddanol ()-displayed PD-L1 binding activity. Laser scanning confocal microscopy results demonstrated that these compounds effectively inhibited the binding of PD-1 to PD-L1 in a dose-dependent manner. Additionally, flow cytometry analysis indicated they could promote human lung cancer cell line (A549) apoptosis when co-cultured with Peripheral Blood Mononuclear Cells (PBMCs). The system's innovation lies in its first integration of dynamic protein-ligand trapping with multi-dimensional validation, coupled with high-throughput screening capacity for structurally diverse natural products. This workflow overcomes traditional phytochemical screening bottlenecks by preserving native protein conformations during affinity capture while maintaining chromatographic resolution, offering a transformative template for accelerating natural product-derived immunotherapeutics through the PD-1/PD-L1 pathway.
中草药在新型有效药物的研发中发挥了重要作用,但如何从复杂的中草药提取物中鉴定出活性成分是一个研究难题。近年来,很少有研究聚焦于高效鉴定具有较低抗原性和灵活结构可调性的程序性死亡配体1小分子抑制剂。为了从复杂的中草药提取物中鉴定出PD-L1小分子抑制剂,本研究基于高效液相色谱结合光电二极管阵列检测器、离子阱/四极杆飞行时间串联质谱以及程序性死亡配体1亲和色谱单元(ACPD-L1-HPLC-PDA-IT-TOF(Q-TOF)-MS)建立了一种蛋白质-配体捕获系统,以快速筛选和鉴定来自毛花洋地黄(L.)Lam.中的程序性死亡配体1小分子抑制剂。随后鉴定出14种成分作为PD-L1结合剂,表面等离子体共振(SPR)验证结果表明,其中6种——木兰花碱()、两面针碱()、白屈菜红碱()、药根碱()、托大库林()和托大醇()——具有PD-L1结合活性。激光扫描共聚焦显微镜结果表明,这些化合物以剂量依赖性方式有效抑制PD-1与PD-L1的结合。此外,流式细胞术分析表明,当与外周血单个核细胞(PBMCs)共培养时,它们可促进人肺癌细胞系(A549)凋亡。该系统的创新之处在于首次将动态蛋白质-配体捕获与多维验证相结合,并具备对结构多样的天然产物的高通量筛选能力。这种工作流程通过在亲和捕获过程中保留天然蛋白质构象同时保持色谱分辨率,克服了传统植物化学筛选的瓶颈,为通过PD-1/PD-L1途径加速天然产物衍生的免疫疗法提供了一个变革性模板。